SGLT2 inhibitor empagliflozin: finally at the latter stage of understanding?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 29291819.
- Also identified by DOI 10.1016/j.kint.2017.07.008.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Sodium glucose cotransporter 2 inhibitors are a relatively new adjunctive treatment option for type 2 diabetes (T2D). Extraglycemic benefits of sodium glucose cotransporter 2 inhibition include weight and blood pressure reduction. Cherney et al. now demonstrate that these extraglycemic properties of empagliflozin are preserved despite reduced urinary glucose excretion in advancing chronic kidney disease. Limited therapeutic options for patients with type 2 diabetes in the latter stages of chronic kidney disease make empagliflozin an attractive therapeutic agent with additional cardiovascular benefits.
Medical subject headings
- Diabetes Mellitus, Type 2
- Sodium-Glucose Transporter 2